Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis, spinal muscular atrophy (SMA) type 3, and infantile spasms. The company was founded by Huckel E. Hubert and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing and commercializing novel medicines for patients living with rare diseases including Lambert-Eaton myasthenic syndrome, congenital myasthenic syndromes, MuSK antibody positive myasthenia gravis, spinal muscular atrophy type 3, and infantile spasms. The company was founded by Huckel E. Hubert and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.

CORAL GABLES, Fla., Jan. 28, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases, today reported that the U.S. Court of Appeals for the 11th Circuit has issued a mandate directing the District Court that heard Catalyst's claim against the FDA to enter summary judgment in favor of Catalyst in its lawsuit against the FDA, thereby vacating the FDA's approval of Ruzurgi® (Jacobus Pharmaceutical Company's amifampridine product).

Catalyst Pharmaceuticals Announces Issuance of Mandate by the U.S. Court of Appeals for the 11th Circuit Directing the District Court Judge in Catalyst's Lawsuit Against the FDA to Grant Summary Judgement in Favor of Catalyst

AbbVie

Horizon Pharma

Innoviva

Eli Lilly

Pfizer

Zoetis

As the market begins to shift from high-growth, tech-fueled start-ups, one good long-term growth option is quality pharmaceutical stocks. The post 7 of the Top-Rated Pharmaceutical Stocks for Q1 appeared first on InvestorPlace.

7 of the Top-Rated Pharmaceutical Stocks for Q1

CORAL GABLES, Fla., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases, today reported that the 11th Circuit Court of Appeals has denied Jacobus Pharmaceutical Company Inc.'s petition for rehearing of the 11th Circuit's prior ruling to overturn the U.S. Food and Drug Administration (FDA) approval of Ruzurgi® for pediatric patients with Lambert-Eaton myasthenic syndrome (LEMS) based on the orphan drug exclusivity of FIRDAPSE®. Catalyst expects that the mandate to the District Court with instructions to enter summary judgment for Catalyst will be issued in the near future.

Catalyst Pharmaceuticals Announces 11th Circuit Court of Appeals Denial of Jacobus Pharmaceutical Company Inc.'s Petition for Rehearing

Corcept Therapeutics

These quiet biotechs are tightly focused and practically alone in their markets.

2 Under-the-Radar Biotech Picks to Buy For The Long Haul

Vaxart

They've strongly outperformed the market in the past, and they could easily do it again.

2 Top Healthcare Stocks Ready for a Bull Run in 2022

CORAL GABLES, Fla., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases, today announced that its collaboration partner DyDo Pharma ("DyDo") has initiated a Phase 3 registrational study in Japan to evaluate the efficacy and safety of Catalyst's FIRDAPSE® (amifampridine) 10 mg tablets for the treatment of Lambert-Eaton myasthenic syndrome ("LEMS").

Catalyst Pharmaceuticals Announces DyDo Pharma Initiation of a Phase 3 Study for FIRDAPSE® (amifampridine) in Japan

CORAL GABLES, Fla., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases, today announced that Patrick J. McEnany, Catalyst's Chief Executive Officer and Steven Miller, Ph.D., Chief Scientific Officer/COO, will participate at the Piper Sandler 33rd Annual Virtual Healthcare Conference being held on November 29, 2021 through December 2, 2021.

Catalyst Pharmaceuticals to Participate at the Piper Sandler 33rd Annual Virtual Healthcare Conference

The average of price targets set by Wall Street analysts indicates a potential upside of 29.6% in Catalyst (CPRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

How Much Upside is Left in Catalyst (CPRX)? Wall Street Analysts Think 30%

Catalyst Pharmaceuticals, Inc. (CPRX) CEO Patrick McEnany on Q3 2021 Results - Earnings Call Transcript

Catalyst's (CPRX) earnings meet estimates in the third quarter of 2021 while revenues beat the same.

Catalyst's (CPRX) Q3 Earnings In Line, Revenues Beat Estimates

Catalyst (CPRX) delivered earnings and revenue surprises of 0.00% and 4.30%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Catalyst Pharmaceutical (CPRX) Q3 Earnings Meet Estimates

Continued Strong Financial and Operational Performance in the Third Quarter 2021 FIRDAPSE® Revenue of $35.9 Million Increased 23.1% Compared to Third Quarter 2020 Plans to Seek to Expand the U.S. Approval of FIRDAPSE To Include Pediatric LEMS Patients Strong Cash Position $174.8 Million Supports Long-term Growth Strategy Company to Host Quarterly Conference Call on November 10, 2021, at 8:30 AM ET

Catalyst Pharmaceuticals Reports Third Quarter 2021 Financial Results

Nokia

Sirius XM Hlds

With all three of the major indexes continuing to break records, it may seem like most stocks are trading at very high prices. But there are still plenty of low-priced stocks that would make great additions to your portfolio.

3 Low-Priced Stocks That Make Smart Bets

Catalyst (CPRX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Catalyst (CPRX) Is a Great Choice for "Trend" Investors, Here's Why

Catalyst (CPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Catalyst Pharmaceutical (CPRX) Q3 Earnings Expected to Decline

Enanta Pharmaceuticals

Molecular Templates

Xencor

Some residual impact of the coronavirus pandemic is expected on the Medical-Drugs industry players' third-quarter results. XNCR, ENTA, CPRX and MTEM may prove to be good additions to one's portfolio.

4 Small Drug Stocks That Hold Promise Despite Industry Challenges

The Company will host a Conference Call and Webcast on November 10, 2021, at 8:30 AM EST The Company will host a Conference Call and Webcast on November 10, 2021, at 8:30 AM EST

Catalyst Pharmaceuticals to Report Third Quarter 2021 Financial Results on November 9, 2021

Vericel

CRISPR Therapeutics

Hint: it doesn't really matter what kind of market it is.

How to Invest in Biotech Stocks in a Bear Market

Catalyst (CPRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Strength Seen in Catalyst (CPRX): Can Its 6.9% Jump Turn into More Strength?

Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) shares are trading higher Wednesday although there looks to be no company-evident news to explain the jump in price. The stock is trading on above-average volume and trending on social media sites.

Catalyst Pharmaceuticals Stock Reaches Resistance Level, Looks Ready To Break Out

Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) has received a favorable decision from the 11th Circuit Court of Appeals in its appeal to overturn a District Court decision upholding the FDA approval of another amifampridine product, Ruzurgi, despite existing Orphan Drug exclusivity for Catalyst's Firdapse (amifampridine). Amifampridine products are indicated for Lambert-Eaton myasthenic syndrome (LEMS), a rare autoimmune disorder that affects the connection between nerves and muscles.

Why Are Catalyst Pharma Shares Trading Higher On Thursday?

CORAL GABLES, Fla., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases, today reported that it has received a positive decision from the 11th Circuit Court of Appeals in its appeal to overturn a District Court decision upholding the U.S. Food and Drug Administration's (FDA) approval of another amifampridine product, Ruzurgi®, for pediatric patients with Lambert-Eaton myasthenic syndrome (LEMS) despite existing Orphan Drug exclusivity for Catalyst's Firdapse® (amifampridine) Tablets 10 mg.

Catalyst Pharmaceuticals Receives Positive Decision from Appeals Court That Supports Orphan Drug Exclusivity for Firdapse® for LEMS

Green Plains Partners

Sibanye Stillwater

Selecting U.S.-listed equities that have the characteristics listed below represents a solid starting point when in search of potential value opportunities, in my opinion:

A Trio of Stock Picks With Growth Potential

CORAL GABLES, Fla., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases, today announced that Patrick J. McEnany, Catalyst's Chief Executive Officer and Steven Miller, Ph.D., Chief Scientific Officer /COO, will participate at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit.

Catalyst Pharmaceuticals to Participate at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock?

News for Catalyst Pharmaceuticals Stock (CPRX)